ERBB2 and breast carcinoma: Lack of benefit from adjuvant CMF or cyclophosphamide was predicted by the Prosigna Risk Of Recurrence (ROR) score and by intrinsic subtypes in a recent retrospective analysis of the Danish Breast Cancer Group (DBCG) 77B trial that randomized premenopausal high-risk patients with early breast cancer to adjuvant chemotherapy vs. no chemotherapy.7 A Basal-like subtype was associated with an 86% reduction in disease-free survival (DFS) event while no benefit was obtained by patients with an HER2-enriched subtype.